We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

177 hedge funds and large institutions have $1.28B invested in Allogene Therapeutics in 2021 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 68 increasing their positions, 42 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

62% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 42

38% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 29

13% more call options, than puts

Call options by funds: $2.29M | Put options by funds: $2.02M

5% more funds holding

Funds holding: 169 → 177 (+8)

1.66% less ownership

Funds ownership: 61.87% → 60.21% (-1.7%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

43% less capital invested

Capital invested by funds: $2.26B → $1.28B (-$981M)

Holders
177
Holders Change
+8
Holders Change %
+4.73%
% of All Funds
2.72%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
40
Increased
68
Reduced
42
Closed
29
Calls
$2.29M
Puts
$2.02M
Net Calls
+$271K
Net Calls Change
+$2.27M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$36.4M
2
Primecap Management
Primecap Management
California
+$18.7M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$17M
4
Marshall Wace
Marshall Wace
United Kingdom
+$16.7M
5
State Street
State Street
Massachusetts
+$15.9M

Top Sellers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
-$139M
2
AllianceBernstein
AllianceBernstein
Tennessee
-$55.2M
3
Capital International Investors
Capital International Investors
California
-$34.5M
4
PHS
PFM Health Sciences
California
-$19.9M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$19.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$8.01M +$107K +6,049 +1%
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$7.91M +$8.95M +507,107 +2,233%
WP
28
Woodline Partners
California
$7.46M -$5.52M -312,635 -38%
Nordea Investment Management
29
Nordea Investment Management
Sweden
$6.46M +$1.98M +112,028 +37%
UBS AM
30
UBS AM
Illinois
$5.82M +$35.7K +2,021 +0.5%
Deutsche Bank
31
Deutsche Bank
Germany
$5.14M +$2.35M +132,937 +63%
N
32
Nuveen
North Carolina
$5.09M -$1.84M -104,476 -23%
SC
33
Sessa Capital
New York
$4.99M -$7.33M -415,604 -55%
CBA
34
Coastal Bridge Advisors
Connecticut
$4.5M +$12.2K +689 +0.2%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$4.46M -$355K -20,127 -6%
Rafferty Asset Management
36
Rafferty Asset Management
New York
$4.41M +$2.9M +164,098 +125%
PC
37
Pier Capital
Connecticut
$4.4M -$2.74M -155,214 -34%
Voloridge Investment Management
38
Voloridge Investment Management
Florida
$4.2M +$4.96M +281,386 New
Bank of America
39
Bank of America
North Carolina
$4.02M +$3.74M +211,768 +366%
Citigroup
40
Citigroup
New York
$3.96M +$2.45M +138,729 +110%
SCM
41
Suvretta Capital Management
New York
$3.96M +$4.68M +265,116 New
Mirae Asset Global Investments
42
Mirae Asset Global Investments
South Korea
$3.77M +$642K +36,378 +17%
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$3.65M +$2.52M +142,706 +140%
Principal Financial Group
44
Principal Financial Group
Iowa
$3.55M +$1.71M +97,060 +69%
EVM
45
Eaton Vance Management
Massachusetts
$3.54M – – –
Sumitomo Mitsui Trust Group
46
Sumitomo Mitsui Trust Group
Japan
$3.05M +$3.6M +204,156 New
NAMA
47
Nikko Asset Management Americas
New York
$2.98M +$3.6M +204,156 New
GC
48
Gratus Capital
Georgia
$2.86M +$3.39M +191,871 New
Two Sigma Investments
49
Two Sigma Investments
New York
$2.83M +$3.35M +189,791 New
PP
50
PDT Partners
New York
$2.78M +$2.25M +127,355 +217%
1
2
3 4 5

ALLO Hedge Fund Activity: Q4 2021 in Review

177 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2021, worth a combined $1.28B — down 43% from $2.26B a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new ALLO positions and 29 closed out — a net gain of 11 holders — while 68 added to existing stakes and 42 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $36.4M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $139M sold.

  • 177 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2021, up from 169 in Q3 2021.
  • Funds reported $1.28B of Allogene Therapeutics stock for Q4 2021, down 43% quarter-over-quarter.
  • 40 funds opened new Allogene Therapeutics positions in Q4 2021 and 29 closed out, a net change of +11 holders.
  • The largest Allogene Therapeutics buyer in Q4 2021 was Citadel Advisors, an estimated $36.4M added.
  • The largest Allogene Therapeutics seller in Q4 2021 was Capital Research Global Investors, an estimated $139M sold.

Based on aggregated 13F filings for Q4 2021.